KRAS and lung adenocarcinoma: For example, erlotinib-treated spheroids derived from patient lung adenocarcinoma, showed a major increase in PIK3CA H1047R mutant subpopulations compared to BRAF V600E, KRAS G12D, KRAS G12V, and PIK3CA H1047R mutant cells, which aligns with what happens in patients.